Written by Jane Aubrey
The FDA has expanded the accelerated approval of sevabertinib, marketed as Hyrnuo, for adults with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors carry HER2, also called ERBB2, tyrosine-kinase-domain activating mutations. The September 9 decision extends eligibility to patients who have not received prior systemic therapy, rather than limiting the indication to the previously treated population. It is an important regulatory step for a molecularly selected group with a difficult disease. It should also be read through the framework the FDA used: accelerated approval based on response evidence, with the continuing need to establish clinical benefit and manage meaningful safety risks.
The agency evaluated efficacy in SOHO-01, an open-label, single-arm, multicenter, multi-cohort study. For the 69 patients with the relevant HER2 mutation who had not received prior systemic therapy, the confirmed objective response rate was 75%, with a 95% confidence interval of 64% to 85%. Among responding patients, 73% had a duration of response of at least six months and 38% had a duration of response of at least 12 months. Responses and duration were assessed by blinded independent central review using RECIST 1.1. These are substantial measures of antitumor activity in a genomically defined cohort, and they explain why the regulator considered the evidence adequate for accelerated approval.
At the same time, the study design shapes what the numbers can establish. A single-arm study does not include a randomized control group receiving another therapy or standard care. That makes it harder to isolate the treatment effect from patient selection, disease biology, follow-up patterns or differences in supportive care. Objective response rate can be a meaningful endpoint in oncology, particularly when responses are independently reviewed and durable. It is not identical to evidence that a treatment improves overall survival, progression-free survival, symptoms or quality of life compared with an alternative. Accelerated approval is designed to allow earlier access in serious conditions while preserving the obligation to verify benefit.
The biomarker requirement is central. The indication applies only when an FDA-authorized test identifies a HER2/ERBB2 tyrosine-kinase-domain activating mutation. HER2 is not one interchangeable clinical label across all tumors or even across all lung-cancer alterations. Testing method, specimen quality, interpretation and the exact molecular alteration determine whether a patient fits the approved population. In practice, the decision reinforces the role of comprehensive molecular diagnostics at the point when treatment choices are made. It also means that results from this selected group should not be generalized to patients with other HER2 findings or other forms of lung cancer.
Safety management remains part of the benefit-risk equation. The FDA-approved prescribing information includes warnings and precautions for diarrhea, hepatotoxicity, interstitial lung disease or pneumonitis, left-ventricular dysfunction, ocular toxicity, pancreatic-enzyme elevation and embryo-fetal toxicity. These are not routine footnotes. They influence baseline assessment, monitoring, dose interruption or discontinuation decisions, counseling and the choice between therapies for an individual patient. The recommended dosage is 20 mg orally twice daily with food until disease progression or unacceptable toxicity, but clinical use requires attention to the label and to the patient’s full medical context.
The expansion was reviewed under Project Orbis, through which the FDA collaborated with the United Kingdom’s MHRA; the FDA says reviews remain ongoing at other participating agencies. The application also received priority review, while the drug has breakthrough-therapy and orphan-drug designations. These pathways can speed assessment or support development in serious diseases. They do not remove the scientific distinction between an early regulatory authorization based on a surrogate measure and a completed demonstration of long-term comparative clinical benefit.
For patients and clinicians, the practical significance is that a targeted oral option is now available earlier in the treatment sequence for the specified HER2-mutant non-squamous NSCLC population. For researchers and regulators, the key follow-up questions are whether clinical benefit is confirmed, how durable benefits remain with broader use, and how the safety profile performs outside a small single-arm cohort. The FDA action expands access while making the evidence standard visible: a high response rate can justify acceleration, but confirmation determines the enduring place of a therapy in care.
This article is informational and educational only, not medical advice. Decisions about cancer treatment should be made with qualified oncology clinicians using the current prescribing information, authoritative evidence and individual circumstances.
